MCID: LTR001
MIFTS: 60

Lateral Sclerosis

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lateral Sclerosis

MalaCards integrated aliases for Lateral Sclerosis:

Name: Lateral Sclerosis 12 15 73
Primary Lateral Sclerosis 12 76 53 54 55
Adult-Onset Primary Lateral Sclerosis 12 53
Motor Neuron Disease 44 73
Adult-Onset Pls 53

Classifications:



External Ids:

Disease Ontology 12 DOID:230
ICD10 33 G12.23
ICD9CM 35 335.24
MeSH 44 D016472
NCIt 50 C129933
SNOMED-CT 68 81211007

Summaries for Lateral Sclerosis

NIH Rare Diseases : 53 Primary lateral sclerosis (PLS) is a rare neuromuscular disease that affects the nerve cells that control the voluntary muscles. Problems in the legs (such as weakness, stiffness, spasticity, and balance problems) are often observed first, but hand clumsiness and changes in speech can be early symptoms, as well. The condition is progressive (gradually becomes worse over time); however, affected people have a normal life expectancy. The underlying cause of adult PLS is currently unknown. In most cases, it occurs sporadically in people with no family history of the condition. A subtype of PLS, called juvenile PLS, is caused by changes (mutations) in the ALS2 gene and is inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Lateral Sclerosis, also known as primary lateral sclerosis, is related to amyotrophic lateral sclerosis 2, juvenile and primary lateral sclerosis, adult, 1, and has symptoms including ataxia, myoclonus and hemiplegia. An important gene associated with Lateral Sclerosis is ALS2 (ALS2, Alsin Rho Guanine Nucleotide Exchange Factor), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Riluzole and Mexiletine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs.

Wikipedia : 76 Primary lateral sclerosis (PLS) is a rare neuromuscular disease characterized by progressive muscle... more...

Related Diseases for Lateral Sclerosis

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile Primary Lateral Sclerosis, Adult, 1

Diseases related to Lateral Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 386)
# Related Disease Score Top Affiliating Genes
1 amyotrophic lateral sclerosis 2, juvenile 34.4 ALS2 ALS2CR12 SOD1
2 primary lateral sclerosis, adult, 1 34.3 ALS2 SOD1
3 amyotrophic lateral sclerosis 4, juvenile 34.3 ALS2 SETX
4 amyotrophic lateral sclerosis type 6 34.3 ALS2 FUS SETX TARDBP
5 amyotrophic lateral sclerosis 16, juvenile 34.2 ALS2 SIGMAR1 SOD1
6 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 34.2 C9orf72 CHCHD10 FUS TARDBP UBQLN2 VCP
7 amyotrophic lateral sclerosis 18 34.1 C9orf72 FUS SOD1 TARDBP
8 juvenile amyotrophic lateral sclerosis 34.1 ALS2 FUS SETX SIGMAR1
9 amyotrophic lateral sclerosis 20 34.0 ALS2 HNRNPA1
10 amyotrophic lateral sclerosis 10 with or without frontotemporal dementia 34.0 ALS2 ANG FIG4 FUS SETX TARDBP
11 amyotrophic lateral sclerosis 11 34.0 ALS2 ANG FIG4 FUS SETX TARDBP
12 amyotrophic lateral sclerosis 9 34.0 ALS2 ANG FIG4 FUS SETX TARDBP
13 amyotrophic lateral sclerosis 21 33.9 C9orf72 FUS SETX SOD1 TARDBP VAPB
14 amyotrophic lateral sclerosis 7 33.9 ALS2 ANG FIG4 FUS SETX TARDBP
15 amyotrophic lateral sclerosis type 14 33.9 FUS TARDBP UBQLN2 VAPB VCP
16 frontotemporal dementia 32.9 C9orf72 CHCHD10 FUS HNRNPA1 NEFH SOD1
17 amyotrophic lateral sclerosis 1 32.6 ALS2 ANG C9orf72 CHCHD10 DCTN1 FIG4
18 progressive muscular atrophy 32.4 C9orf72 TARDBP
19 motor neuron disease 31.9 ALS2 C9orf72 CHCHD10 DCTN1 FUS NEFH
20 distal hereditary motor neuropathies 31.8 DCTN1 SETX
21 perry syndrome 31.7 C9orf72 DCTN1 TARDBP
22 nervous system disease 31.6 C9orf72 SOD1 TARDBP
23 dementia 30.8 C9orf72 CHCHD10 FUS HNRNPA1 TARDBP TRPM7
24 spinal muscular atrophy 30.6 CHCHD10 HNRNPA1 SIGMAR1 VAPB
25 progressive non-fluent aphasia 30.1 C9orf72 VCP
26 brown-vialetto-van laere syndrome 30.1 ALS2 C9orf72 SOD1 TARDBP UBQLN2
27 charcot-marie-tooth disease 30.0 DCTN1 FIG4 NEFH SETX VCP
28 behavioral variant of frontotemporal dementia 29.9 C9orf72 VCP
29 postpoliomyelitis syndrome 29.9 TARDBP VCP
30 semantic dementia 29.8 C9orf72 TARDBP
31 primary lateral sclerosis, juvenile 12.7
32 madras motor neuron disease 12.7
33 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 12.7
34 amyotrophic lateral sclerosis 8 12.7
35 amyotrophic lateral sclerosis 19 12.6
36 amyotrophic lateral sclerosis 6 with or without frontotemporal dementia 12.5
37 amyotrophic lateral sclerosis 17 12.5
38 amyotrophic lateral sclerosis 12 12.5
39 amyotrophic lateral sclerosis 14 with or without frontotemporal dementia 12.5
40 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 12.5
41 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 12.5
42 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 12.5
43 amyotrophic lateral sclerosis 23 12.5
44 amyotrophic lateral sclerosis 15 with or without frontotemporal dementia 12.5
45 amyotrophic lateral sclerosis 3 12.5
46 amyotrophic lateral sclerosis type 5 12.5
47 amyotrophic lateral sclerosis 25 12.5
48 amyotrophic lateral sclerosis 22 with or without frontotemporal dementia 12.5
49 amyotrophic lateral sclerosis 24 12.5
50 amyotrophic lateral sclerosis 5, juvenile 12.4

Graphical network of the top 20 diseases related to Lateral Sclerosis:



Diseases related to Lateral Sclerosis

Symptoms & Phenotypes for Lateral Sclerosis

UMLS symptoms related to Lateral Sclerosis:


ataxia, myoclonus, hemiplegia, muscular fasciculation

GenomeRNAi Phenotypes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.39 DCTN1
2 Decreased viability GR00221-A-1 10.39 TRPM7
3 Decreased viability GR00221-A-2 10.39 SOD1 TRPM7
4 Decreased viability GR00221-A-3 10.39 SOD1
5 Decreased viability GR00221-A-4 10.39 FUS SOD1 TRPM7
6 Decreased viability GR00342-S-2 10.39 TRPM7
7 Decreased viability GR00381-A-1 10.39 ANG FIG4 SIGMAR1 VCP
8 Decreased viability GR00381-A-3 10.39 SIGMAR1
9 Decreased viability GR00402-S-2 10.39 ALS2 ALS2CR12 ANG C9orf72 CHCHD10 DCTN1
10 no effect GR00402-S-1 9.96 ALS2 ALS2CR12 ANG C9orf72 CHCHD10 DCTN1
11 shRNA abundance <= 50% GR00343-S 9.32 ANG FUS HNRNPA1 RNF19A SETX SOD1

MGI Mouse Phenotypes related to Lateral Sclerosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 ALS2 C9orf72 DCTN1 FIG4 NEFH RNF19A
2 cellular MP:0005384 9.9 C9orf72 CHCHD10 DCTN1 NEFH RNF19A SETX
3 muscle MP:0005369 9.5 ALS2 DCTN1 FIG4 SOD1 TARDBP VAPB
4 nervous system MP:0003631 9.4 ALS2 C9orf72 DCTN1 FIG4 NEFH PRPH

Drugs & Therapeutics for Lateral Sclerosis

Drugs for Lateral Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1744-22-5 5070
2
Mexiletine Approved, Investigational Phase 4,Phase 2 31828-71-4 4178
3
Armodafinil Approved, Investigational Phase 4 112111-43-0
4
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
5 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
6 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
12 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Phase 1
13 Sodium Channel Blockers Phase 4,Phase 3,Phase 2,Phase 1
14 Cytochrome P-450 CYP3A Inducers Phase 4
15 Central Nervous System Stimulants Phase 4,Phase 1
16 Wakefulness-Promoting Agents Phase 4
17
Olanzapine Approved, Investigational Phase 2, Phase 3 132539-06-1 4585
18
Iron Approved Phase 2, Phase 3,Not Applicable 7439-89-6 23925
19
Lithium carbonate Approved Phase 2, Phase 3 554-13-2
20
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3,Phase 3 13422-55-4
21
Dopamine Approved Phase 2, Phase 3,Phase 3,Phase 1 51-61-6, 62-31-7 681
22
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
23
Antipyrine Approved, Investigational Phase 3,Phase 1,Phase 2 60-80-0 2206
24
Hydroxocobalamin Approved Phase 2, Phase 3,Phase 3 13422-51-0 11953898 44475014
25
Zinc Approved, Investigational Phase 3,Phase 1,Phase 2 7440-66-6
26
Mecasermin Approved, Investigational Phase 3 68562-41-4
27
Lenograstim Approved, Investigational Phase 2, Phase 3,Not Applicable 135968-09-1
28
Pramipexole Approved, Investigational Phase 3,Phase 1,Phase 2 104632-26-0 119570 59868
29
Minocycline Approved, Investigational Phase 3,Phase 2 10118-90-8 5281021
30
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
31
Valproic Acid Approved, Investigational Phase 3,Phase 2 99-66-1 3121
32
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
33
Acetylcholine Approved Phase 2, Phase 3,Phase 3,Not Applicable 51-84-3 187
34
Quinidine Approved, Investigational Phase 3,Phase 2 56-54-2 441074
35
Dextromethorphan Approved Phase 3,Phase 2 125-71-3 5360696 5362449
36
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2 93-14-1 3516
37
Citalopram Approved Phase 3 59729-33-8 2771
38
Deferiprone Approved Phase 2, Phase 3,Not Applicable 30652-11-0 2972
39
Creatine Approved, Investigational, Nutraceutical Phase 3,Phase 2 57-00-1 586
40
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 68-19-9 44176380
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 59-30-3 6037
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
43
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3,Phase 2 303-98-0 5281915
44
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
45
Cobalamin Experimental Phase 2, Phase 3,Phase 3 13408-78-1 6438156
46 Tocotrienol Investigational Phase 3 6829-55-6
47 Simendan Investigational Phase 3,Phase 2 131741-08-7
48 Antiemetics Phase 2, Phase 3
49 Antipsychotic Agents Phase 2, Phase 3,Phase 3
50 Psychotropic Drugs Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 503)
# Name Status NCT ID Phase Drugs
1 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
2 CARE Canadian ALS Riluzole Evaluation Completed NCT00542412 Phase 4 Riluzole
3 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
4 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
5 Modafinil for Treatment of Fatigue in ALS Patients Completed NCT00614926 Phase 4 Modafinil;Placebo
6 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
7 Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3 Olanzapine
8 Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3 Creatine Monohydrate
9 Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Completed NCT02588677 Phase 2, Phase 3 Masitinib (4.5);Riluzole;Placebo;Masitinib (3.0)
10 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00445172 Phase 2, Phase 3 E0302 (mecobalamin)
11 Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) Completed NCT00353665 Phase 2, Phase 3 Memantine (Ebixa);riluzole;Placebo
12 Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis Completed NCT01492686 Phase 3 MCI-186;Placebo;MCI-186 in open label phase
13 A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3 E0302 (mecobalamin);E0302 (mecobalamin);Placebo
14 Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis Completed NCT00706147 Phase 2, Phase 3 Arimoclomol;Placebo
15 Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00424463 Phase 3 MCI-186;Placebo of MCI-186
16 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial Completed NCT00035815 Phase 3 Insulin like growth factor, type 1;Placebo
17 The Effect of GCSF in the Treatment of ALS Patients Completed NCT01825551 Phase 2, Phase 3 Granulocyte Colony Stimulating Factor;Placebo
18 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Completed NCT00330681 Phase 3 MCI-186;Placebo of MCI-186
19 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III Completed NCT00415519 Phase 3 MCI-186;Placebo of MCI-186
20 Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Completed NCT00868166 Phase 2, Phase 3 Olesoxime;Placebo Comparator
21 Phase 3 Study of Dexpramipexole in ALS Completed NCT01281189 Phase 3 Dexpramipexole;Placebo
22 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT01933321 Phase 2, Phase 3
23 Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis Completed NCT00833820 Phase 2, Phase 3
24 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3 minocycline
25 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls Completed NCT01160263 Phase 3 SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
26 Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS Completed NCT00372879 Phase 3
27 Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis Completed NCT00136110 Phase 3 Sodium Valproate
28 Clinical Trial Ceftriaxone in Subjects With ALS Completed NCT00349622 Phase 3 ceftriaxone
29 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00125203 Phase 2, Phase 3 Botulinum toxin type B (Myobloc)
30 A Study for Patients Who Completed VITALITY-ALS (CY 4031) Completed NCT02936635 Phase 3 tirasemtiv
31 Safety Extension Study of TRO19622 in ALS Completed NCT01285583 Phase 2, Phase 3 TRO19622
32 Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Completed NCT02496767 Phase 3 tirasemtiv;Placebo tablets;Riluzole 50 MG
33 Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS Completed NCT00021697 Phase 3 AVP-923
34 Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
35 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement Completed NCT00386464 Phase 2, Phase 3
36 Escitalopram (Lexapro) for Depression MS or ALS Completed NCT00965497 Phase 3 escitalopram
37 Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Completed NCT01776970 Phase 2, Phase 3 Cannabis Sativa extract Oromucosal spray
38 Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) Completed NCT01257828 Phase 3 riluzole;Placebo medication
39 Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3 MYOBLOC
40 Arimoclomol in Amyotropic Lateral Sclerosis Recruiting NCT03491462 Phase 3 Arimoclomol;Placebo oral capsule
41 Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease Recruiting NCT03690791 Phase 3 CannTrust CBD Oil (capsule);Placebo (capsule)
42 Clinical Trial of Ultra-high Dose Methylcobalamin for ALS Recruiting NCT03548311 Phase 3 methylcobalamin;saline solution
43 Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients Recruiting NCT03280056 Phase 3
44 Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS Recruiting NCT03505021 Phase 3 Levosimendan;Placebo for levosimendan
45 Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) Recruiting NCT03347344 Phase 3 Riluzole;Placebo
46 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Not yet recruiting NCT03293069 Phase 2, Phase 3 Deferiprone;Placebo Oral Tablet
47 Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients Not yet recruiting NCT03127267 Phase 3 Masitinib (6.0);Riluzole;Placebo;Masitinib (4.5)
48 Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS Not yet recruiting NCT03800524 Phase 3 Tauroursodeoxycholic acid (TUDCA);Placebo
49 Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Terminated NCT00818389 Phase 2, Phase 3 Lithium Carbonate;Riluzole;placebo
50 Phase 3 Extension Study of Dexpramipexole in ALS Terminated NCT01622088 Phase 3 Dexpramipexole

Search NIH Clinical Center for Lateral Sclerosis

Cochrane evidence based reviews: motor neuron disease

Genetic Tests for Lateral Sclerosis

Anatomical Context for Lateral Sclerosis

MalaCards organs/tissues related to Lateral Sclerosis:

41
Spinal Cord, Brain, Bone, Testes, Cortex, Bone Marrow, Skeletal Muscle

Publications for Lateral Sclerosis

Articles related to Lateral Sclerosis:

(show top 50) (show all 3674)
# Title Authors Year
1
Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia. ( 30348461 )
2019
2
Elucidating the End-of-Life Experience of Persons With Amyotrophic Lateral Sclerosis. ( 30422919 )
2019
3
Amyotrophic lateral sclerosis as a synaptopathy. ( 30530995 )
2019
4
Amyotrophic lateral sclerosis: a complex syndrome that needs an integrated research approach. ( 30530996 )
2019
5
Safety of intrathecal injection of Wharton's jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy. ( 30531015 )
2019
6
Misdiagnosis: Hypoglossal palsy mimicking bulbar onset amyotrophic lateral sclerosis. ( 30555942 )
2019
7
Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. ( 30290270 )
2019
8
Mutation analysis of KIF5A in Chinese amyotrophic lateral sclerosis patients. ( 30301576 )
2019
9
Genetic activation of parkin rescues TAF15-induced neurotoxicity in a Drosophila model of amyotrophic lateral sclerosis. ( 30339961 )
2019
10
UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. ( 30368160 )
2019
11
Defective daily temperature regulation in a mouse model of amyotrophic lateral sclerosis. ( 30031021 )
2019
12
Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial. ( 30124008 )
2019
13
Coexistence of Amyotrophic Lateral Sclerosis in the Proband of an X-Linked Charcot-Marie-Tooth Disease Type 1 Pedigree in China. ( 29629536 )
2018
14
Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. ( 29427042 )
2018
15
Imaging of glia activation in people with primary lateral sclerosis. ( 29159046 )
2018
16
Successful Management of Acquired Tracheomalacia of Patients With Amyotrophic Lateral Sclerosis: A Report of Three Cases. ( 29765893 )
2018
17
Whole blood transcriptome analysis in amyotrophic lateral sclerosis: A biomarker study. ( 29939990 )
2018
18
Therapeutic effects of percutaneous endoscopic gastrostomy on survival in patients with amyotrophic lateral sclerosis: A meta-analysis. ( 29408898 )
2018
19
EFFECT OF WEDELOLACTONE AND GALLIC ACID ON QUINOLINIC ACID-INDUCED NEUROTOXICITY AND IMPAIRED MOTOR FUNCTION: SIGNIFICANCE TO SPORADIC AMYOTROPHIC LATERAL SCLEROSIS. ( 29981346 )
2018
20
Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis. ( 29950436 )
2018
21
Impact of expiratory strength training in amyotrophic lateral sclerosis: Results of a randomized sham controlled trial. ( 29981250 )
2018
22
Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. ( 29254092 )
2018
23
A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy. ( 29416499 )
2018
24
Elevated Global DNA Methylation Is Not Exclusive to Amyotrophic Lateral Sclerosis and Is Also Observed in Spinocerebellar Ataxia Types 1 and 2. ( 29428949 )
2018
25
Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. ( 29941342 )
2018
26
Crush injury to motor nerves in the G93A transgenic mouse model of amyotrophic lateral sclerosis promotes muscle reinnervation and survival of functionally intact nerve-muscle contacts. ( 29409912 )
2018
27
Swallowing impairments in Amyotrophic Lateral Sclerosis and Myotonic Dystrophy type 1: Looking for the portrait of dysphagic patient in neuromuscular diseases. ( 29400682 )
2018
28
Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. ( 29942091 )
2018
29
A blended psychosocial support program for partners of patients with amyotrophic lateral sclerosis and progressive muscular atrophy: protocol of a randomized controlled trial. ( 29716660 )
2018
30
Molecular mechanisms underlying the impact of mutations in SOD1 on its conformational properties associated with amyotrophic lateral sclerosis as revealed with molecular modelling. ( 29431095 )
2018
31
Amyotrophic Lateral Sclerosis after Receiving the Human Papilloma Virus Vaccine: A Case Report of a 15-year-old Girl. ( 29434138 )
2018
32
Pseudobulbar Affect Correlates With Mood Symptoms in Parkinsonian Disorders but Not Amyotrophic Lateral Sclerosis. ( 29505320 )
2018
33
Radial diffusivity as an imaging biomarker for early diagnosis of non-demented amyotrophic lateral sclerosis. ( 29948064 )
2018
34
Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. ( 29128630 )
2018
35
No Benefit of Diaphragm Pacing in Upper Motor Neuron Dominant Forms of Amyotrophic Lateral Sclerosis. ( 29957023 )
2018
36
Thoracoabdominal asynchrony and paradoxical motion in middle stage amyotrophic lateral sclerosis. ( 29969705 )
2018
37
Association between TBK1 mutations and risk of amyotrophic lateral sclerosis/frontotemporal dementia spectrum: a meta-analysis. ( 29349657 )
2018
38
Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. ( 29417336 )
2018
39
Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum. ( 29868980 )
2018
40
Sharing and Empathy in Digital Spaces: Qualitative Study of Online Health Forums for Breast Cancer and Motor Neuron Disease (Amyotrophic Lateral Sclerosis). ( 29903695 )
2018
41
Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis. ( 29169899 )
2018
42
Motor and extra-motor gray matter integrity may underlie neurophysiologic parameters of motor function in amyotrophic lateral sclerosis: a combined voxel-based morphometry and transcranial stimulation study. ( 29417490 )
2018
43
Association between attention-deficit/hyperactivity disorder (ADHD) and amyotrophic lateral sclerosis (ALS). ( 29961556 )
2018
44
ERp57 is protective against mutant SOD1-induced cellular pathology in Amyotrophic Lateral Sclerosis. ( 29409023 )
2018
45
Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression. ( 29409450 )
2018
46
TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. ( 29954341 )
2018
47
Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. ( 29293261 )
2018
48
Amyotrophic Lateral Sclerosis Model. ( 29951816 )
2018
49
Transcriptomics in amyotrophic lateral sclerosis. ( 28930607 )
2018
50
Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. ( 29955173 )
2018

Variations for Lateral Sclerosis

Expression for Lateral Sclerosis

Search GEO for disease gene expression data for Lateral Sclerosis.

Pathways for Lateral Sclerosis

Pathways related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 DCTN1 NEFH SIGMAR1 SOD1 TARDBP
2
Show member pathways
11.37 DCTN1 NEFH PRPH
3
Show member pathways
10.98 ALS2 NEFH PRPH SOD1

GO Terms for Lateral Sclerosis

Cellular components related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.77 ANG C9orf72 SIGMAR1 SOD1 UBQLN2
2 neuronal cell body GO:0043025 9.55 ALS2 ANG DCTN1 FUS SOD1
3 lipid droplet GO:0005811 9.43 FIG4 SIGMAR1 VCP
4 axon GO:0030424 9.35 ALS2 C9orf72 DCTN1 NEFH SETX
5 growth cone GO:0030426 9.02 ALS2 ANG C9orf72 SETX SIGMAR1
6 cytoplasm GO:0005737 10.17 ALS2 ALS2CR12 C9orf72 DCTN1 FUS HNRNPA1

Biological processes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.33 ALS2 FIG4 SOD1
2 regulation of autophagosome assembly GO:2000785 8.96 C9orf72 UBQLN2
3 neurofilament cytoskeleton organization GO:0060052 8.62 NEFH SOD1

Molecular functions related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.53 ALS2 ALS2CR12 ANG C9orf72 CHCHD10 DCTN1
2 dynein complex binding GO:0070840 8.96 DCTN1 NEFH

Sources for Lateral Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....